Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Springworks Therapeutics (SWTX)
NASDAQ:SWTX
RESEARCH TOOLSreports
Holding SWTX?
Track your performance easily
SWTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$28.21 - $53.92
Previous CloseN/A
Volume729.64K
Average Volume (3M)1.38M
Market Cap
$2.65B
Enterprise Value$2.01B
Total Cash (Recent Filing)$10.27M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 04, 2025EPS Estimate
-0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.73
Shares Outstanding74,386,406
10 Day Avg. Volume2,273,776
30 Day Avg. Volume1,384,612
Standard Deviation0.16
R-Squared0.07
Alpha0.00406
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)19.54
Price to Cash Flow (P/CF)-26.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue14.83
Enterprise Value/Gross Profit399.95
Enterprise Value/Ebitda-11.27
Forecast
1Y Price Target
$65.50Price Target Upside89.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Springworks Therapeutics News
PremiumCompany Announcements
SpringWorks Therapeutics Reports Strong 2024 Financial ResultsBulls Say, Bears Say
Bulls Say
Market Potential And ApprovalA clear view on the Ogsiveo launch shifts investor focus to the potential upcoming approval of mirdametinib in NF1-PN, with expectations of approval in both pediatric and adult markets.
Product Launch And GrowthThe Ogsiveo launch is supported by higher compliance and flat pricing from transition to blister packs, which helps to smooth over dose reductions.
Regulatory ProgressInspections and the late-cycle review are complete on the regulatory side, indicating progress towards approval.
Bears Say
Earnings ReportSpringWorks reported a net loss of $0.72 per share, which was wider than the estimated net loss of $0.60 per share.
Operational ChallengesTransition to blister packs caused delays for many patients in getting their prescriptions refilled.
Sales PerformanceOgsiveo sales were $49 million, falling short of the $52 million consensus expectation.
---
Ownership Overview
2.71% Insiders
33.00% Mutual Funds
0.02% Other Institutional Investors
47.73% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SWTX FAQ
What was Springworks Therapeutics’s price range in the past 12 months?
Springworks Therapeutics lowest stock price was $28.21 and its highest was $53.92 in the past 12 months.
What is Springworks Therapeutics’s market cap?
Springworks Therapeutics’s market cap is $2.65B.
When is Springworks Therapeutics’s upcoming earnings report date?
Springworks Therapeutics’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Springworks Therapeutics’s earnings last quarter?
Springworks Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.754 by $0.034.
Is Springworks Therapeutics overvalued?
According to Wall Street analysts Springworks Therapeutics’s price is currently Undervalued.
Does Springworks Therapeutics pay dividends?
Springworks Therapeutics does not currently pay dividends.
What is Springworks Therapeutics’s EPS estimate?
Springworks Therapeutics’s EPS estimate is -0.67.
How many shares outstanding does Springworks Therapeutics have?
Springworks Therapeutics has 74,386,406 shares outstanding.
What happened to Springworks Therapeutics’s price movement after its last earnings report?
Springworks Therapeutics reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.754. Following the earnings report the stock price went down -1.253%.
Which hedge fund is a major shareholder of Springworks Therapeutics?
Currently, no hedge funds are holding shares in SWTX
---
Springworks Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.50 (89.14% Upside)
$65.50 (89.14% Upside)
Blogger Sentiment
Bullish
SWTX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.81%
12-Months-Change
Fundamentals
Return on Equity
-59.33%
Trailing 12-Months
Asset Growth
30.20%
Trailing 12-Months
Company Description
Springworks Therapeutics
Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.
---
SWTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call displayed a strong performance for OGSIVEO with significant revenue growth and positive market trends. Expansion efforts into Europe and the promising outlook for mirdametinib contribute to a positive sentiment. However, challenges with the blister pack transition and summer seasonality were noted as short-term hurdles.Read More>---
SWTX Stock 12 Month Forecast
Average Price Target
$65.50
▲(89.14% Upside)
Technical Analysis
Blueprint Medicines
―
Karyopharm Therapeutics
―
Seres Therapeutics
―
Fate Therapeutics
―
RegenXBio
―
Immatics
―
Best Analysts Covering SWTX
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+58.01%
reiterated a buy rating 3 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +58.01% per trade.
---